{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-86.5","upperLimit":"43.9","value":"-68.1"},{"groupId":"OG001","lowerLimit":"-73.0","upperLimit":"130.1","value":"-28.0"},{"groupId":"OG002","lowerLimit":"-86.2","upperLimit":"27.1","value":"-55.5"},{"groupId":"OG003","lowerLimit":"-83.7","upperLimit":"-51.2","value":"-70.3"},{"groupId":"OG004","lowerLimit":"-89.0","upperLimit":"-19.6","value":"-54.3"},{"groupId":"OG005","lowerLimit":"-86.2","upperLimit":"-27.1","value":"-78.8"},{"groupId":"OG006","lowerLimit":"-53.8","upperLimit":"-53.8","value":"-53.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"16"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"1"}],"units":"Participants"}],"title":"Day 1 1.5 hours post-dose"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-93.0","upperLimit":"-27.5","value":"-76.1"},{"groupId":"OG001","lowerLimit":"-89.8","upperLimit":"48.6","value":"-34.1"},{"groupId":"OG002","lowerLimit":"-87.7","upperLimit":"-19.5","value":"-84.1"},{"groupId":"OG003","lowerLimit":"-52.2","upperLimit":"-52.2","value":"-52.2"},{"groupId":"OG004","lowerLimit":"-88.6","upperLimit":"-88.6","value":"-88.6"},{"groupId":"OG005","lowerLimit":"-77.5","upperLimit":"-28.2","value":"-52.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"0"}],"units":"Participants"}],"title":"Day 15 1.5 hours post-dose"}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"16"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"1"}],"units":"Participants"}],"description":"Phosphorylated AKT is a biomarker for inhibition of the mammalian target of rapamycin complex 2 (mTORC2). Phosphorylated AKT was measured in stimulated monocytes via flow cytometry. MFI values were determined and converted to molecules of equivalent fluorescence label (MEFL) by normalizing against calibration beads. The biomarker evaluable population included all subjects who took at least one dose of study drug and had at least one non-missing pharmacodynamic (PD) assessment.","dispersionType":"Full Range","groups":[{"description":"Participants with NSCLC received CC-223 at a starting dose of 45 mg/day (reduced to 30 mg/day after protocol Amendment 9) orally once a day in 28-day cycles for as long as they derived benefit from treatment as judged by the investigator.","id":"OG000","title":"Part B: Non-small Cell Lung Cancer (NSCLC)"},{"description":"Participants with GBM received CC-223 at a starting dose of 45 mg/day (reduced to 30 mg/day after protocol Amendment 9) orally once a day in 28-day cycles for as long as they derived benefit from treatment as judged by the investigator.","id":"OG001","title":"Part B: Glioblastoma Multiforme (GBM)"},{"description":"Participants with HCC received CC-223 at a starting dose of 45 mg/day (reduced to 30 mg/day after protocol Amendment 9) orally once a day in 28-day cycles for as long as they derived benefit from treatment as judged by the investigator.","id":"OG002","title":"Part B: Hepatocellular Carcinoma (HCC)"},{"description":"Participants with NET received CC-223 at a starting dose of 45 mg/day (reduced to 30 mg/day after protocol Amendment 9) orally once a day in 28-day cycles for as long as they derived benefit from treatment as judged by the investigator.","id":"OG003","title":"Part B: Neuroendocrine Tumor (NET)"},{"description":"Participants with DLBCL received CC-223 at a starting dose of 45 mg/day (reduced to 30 mg/day after protocol Amendment 9) orally once a day in 28-day cycles for as long as they derived benefit from treatment as judged by the investigator.","id":"OG004","title":"Part B: Diffuse Large B-cell Lymphoma (DLBCL)"},{"description":"Participants with MM received CC-223 at a starting dose of 45 mg/day (reduced to 30 mg/day after protocol Amendment 9) orally once a day in 28-day cycles for as long as they derived benefit from treatment as judged by the investigator.","id":"OG005","title":"Part B: Multiple Myeloma (MM)"},{"description":"Participants with HRPBC received CC-223 at a starting dose of 45 mg/day (reduced to 30 mg/day after protocol Amendment 9) orally once a day in 28-day cycles for as long as they derived benefit from treatment as judged by the investigator.","id":"OG006","title":"Part B: Hormone Receptor Positive Breast Cancer (HRPBC)"}],"paramType":"MEDIAN","populationDescription":"All biomarker evaluable participants who received treatment in Part B.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1: 1.5 hours post-dose and Day 15: 1.5 hours post-dose","title":"Part B: Percent Change From Baseline in Levels of pAKT in Monocytes by Tumor Cohort","type":"SECONDARY","unitOfMeasure":"Percent change in pAKT"}